Dr. Jeffrey Velotta

About Dr. Jeffrey Velotta

Dr. Velotta is a top mesothelioma doctor at Kaiser Permanente in Oakland, California. He’s also a clinical assistant surgical professor at the University of California San Francisco School of Medicine and a renowned mesothelioma researcher.

“I currently have ongoing studies pertaining to novel ways to provide better pain relief after thoracic surgery and multimodality treatment of mesothelioma,” Dr. Velotta tells us. His research focuses on novel and minimally invasive lung cancer surgery techniques. 

He researches image-guided surgeries and develops surgery improvements. He also works on mesothelioma treatment center regionalization and multimodal therapy research.

Medical Education & Experience

Associations, Awards & Recognition

• Society of Asian Academic Surgeons Mid-Career Faculty Award, 2025
• UCSF Medicine’s Academy of Medical Educators Excellence in Mentorship Award, 2024
• Reversing Health Disparities in Lung Cancer Research Award, 2023
• American College of Surgeons 
• Society of Thoracic Surgeons

Why Choose Dr. Jeffrey Velotta for Pleural Mesothelioma 

Thoracic surgeon Dr. Jeffrey Velotta is paving the way for mesothelioma surgery advancements at Kaiser Permanente Oakland Medical Center. He has years of experience in cardiac and thoracic surgery. His dedication has garnered recognition through several awards for his research and mentorship. 

Velotta’s work focuses on minimally invasive lung and esophageal surgery, image-guided surgical techniques for small lung nodules and multimodality mesothelioma care. He remains committed to providing excellent care and the best surgical services for mesothelioma patients.

Publications of Dr. Jeffrey Velotta

• Tupper H.I. et al. (2026, April). Achieving Timely Treatment for Early-Stage Non-Small Cell Lung Cancer: Factors Associated with Delayed Surgical Resection and Proposed Quality Benchmarks.
• Tupper H.I. et al. (2025, June). Time to surgery in early-stage non–small cell lung cancer: Defining the optimal diagnosis-to-resection interval to reduce mortality. Journal of Thoracic and Cardiovascular Surgery.
• Vasic I. et al. (2025, April). Racial/Ethnic Disparities in Lung Cancer Surgery Outcomes in the USA. Epidemiologia.
• Banks K.C. et al. (2025, June). ASO Visual Abstract: The Impact of Preoperative Invasive Nodal Staging on Unexpected Mediastinal Upstaging in Early Stage Non-small Cell Lung Cancer. The Annals of Surgical Oncology.
• Baskin A.S. et al. (2025, October). Outcomes Linked to 3N2+1N1 Sampling by Surgery Type: A Commission on Cancer Lung Cancer Quality Metric. The Annals of Thoracic Surgery Short Reports.
• Yang, M.Z. et al. (2024, September 16). Representativeness of Patients With Lung Cancer in an Integrated Health Care Delivery System.
• Banks K.C. et al. (2024, June). Differences in outcomes by race/ethnicity after thoracic surgery in a large integrated health system. Surgical Open Science.
• Banks, C.K. et al. (2022, January 28). Salvage Resection After Immunotherapy in Refractory Malignant Pleural Mesothelioma.
• Okabe, K. et al. (2021, October 1). The Results of Multimodal Treatment With Extrapleural Pneumonectomy for Female Epithelioid Malignant Pleural Mesothelioma. Journal of Thoracic Oncology.
• Ossowski, S. et al. (2021, October 1). Improving Outcomes in Malignant Pleural Mesothelioma in an Integrated Health System. Journal of Thoracic Oncology.
• Ely, S. et al. (2021, March 19). Effect of thoracic surgery regionalization on long-term survival after lung cancer resection. The Journal of Thoracic and Cardiovascular Surgery.
• Ely, S. et al. (2020, March 14). Regionalization of Lung Cancer Surgery Improves Outcomes in an Integrated Health Care System. The Annals of Thoracic Surgery.